A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD).
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2011
At a glance
- Drugs AZD 7325 (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2009 Actual patient number (725) added as reported by ClinicalTrials.gov.
- 14 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.